Spyre Therapeutics (NASDAQ:SYRE) Upgraded to “Strong-Buy” at Leerink Partnrs
Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) was upgraded by Leerink Partnrs to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports. A number of other research analysts also recently commented on the company. The Goldman Sachs Group upgraded Spyre Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 18th. Wolfe […]
Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) was upgraded by Leerink Partnrs to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports. A number of other research analysts also recently commented on the company. The Goldman Sachs Group upgraded Spyre Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 18th. Wolfe […]